Alan Swinamer

Pyrazole Urea-Based Inhibitors of p38 MAP Kinase:  From Lead Compound to Clinical Candidate

John R. Regan, Steffen Breitfelder, Pier F. Cirillo et al. · Journal of Medicinal Chemistry · 2002 · 350 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

The kinetics of binding to p38 MAP kinase by analogues of BIRB 796

John R. Regan, Christopher A. Pargellis, Pier F. Cirillo et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 111 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +12

Structure−Activity Relationships of the p38α MAP Kinase Inhibitor 1-(5-<i>tert</i>-Butyl-2-<i>p</i>-tolyl-2<i>H</i>-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796)

John R. Regan, Alison J. Capolino, Pier F. Cirillo et al. · Journal of Medicinal Chemistry · 2003 · 106 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +16

Indole RSK inhibitors. Part 2: Optimization of cell potency and kinase selectivity

Thomas M. Kirrane, Stephen J. Boyer, Jennifer Burke et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 41 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Identification of a Potent Sodium Hydrogen Exchanger Isoform 1 (NHE1) Inhibitor with a Suitable Profile for Chronic Dosing and Demonstrated Cardioprotective Effects in a Preclinical Model of Myocardial Infarction in the Rat

John D. Huber, Jörg Bentzien, Stephen J. Boyer et al. · Journal of Medicinal Chemistry · 2012 · 36 citations · Full text

Medicine, Cardiology, Pharmacology +14